(Q37660762)

21 August 2017

1 reference

title

In vitro pharmacodynamic models to determine the effect of antibacterial drugs (English)

1 reference

21 August 2017

1 reference

3

Hartmut Derendorf

1 reference

21 August 2017

Julia Gloede

1

1 reference

21 August 2017

Christian Scheerans

series ordinal

2

1 reference

21 August 2017

Charlotte Kloft

series ordinal

4

1 reference

21 August 2017

language of work or name

English

0 references

publication date

21 December 2009

1 reference

Journal of Antimicrobial Chemotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

65

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

186-201

1 reference

Kinetics of pharmacologic response

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

In vivo antibiotic synergism: contribution of animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Pharmacological indices in antibiotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Historical review of in-vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

A simple dilution analog computer for simulation of drug distribution processes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

How predictive is PK/PD for antibacterial agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Modeling of microbial population responses to time-periodic concentrations of antimicrobial agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

A new modeling approach to the effect of antimicrobial agents on heterogeneous microbial populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

The theory and relevance of continuous culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Correction for bacterial loss in in vitro dilution models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Two compartment kinetic model with multiple artificial capillary units

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

New In Vitro Model to Study the Effect of Antibiotic Concentration and Rate of Elimination on Antibacterial Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Artifacts in dilution pharmacokinetic models caused by adherent bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Evaluation of ceftriaxone and other antibiotics against Escherichia coli, Pseudomonas aeruginosa, and Streptococcus pneumoniae under in vitro conditions simulating those of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Evaluation of two in vitro pharmacodynamic simulation models: microfiltration versus centrifugation-filtration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

A dynamic model for in-vitro evaluation of antimicrobial action by simulation of the pharmacokinetic profiles of antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

In Vitro Model Simulating the Form of Exposure of Bacteria to Antimicrobial Drugs Encountered in Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

An in vitro pharmacodynamic model to simulate antibiotic behavior of acute otitis media with effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Activity of imipenem in an in-vitro model simulating pharmacokinetic parameters in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

New approach for accurate simulation of human pharmacokinetics in an in vitro pharmacodynamic model: application to ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

In vivo verification of in vitro model of antibiotic treatment of device-related infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Development of a tissue culture model for gonococcal invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Development of an integrated semi-automated system for in vitro pharmacodynamic modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Influence of growth rate on susceptibility to antimicrobial agents: modification of the cell envelope and batch and continuous culture studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Differences between in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Evaluation of two methods for overcoming the antibiotic carry-over effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Effects of imipenem on Escherichia coli studied using bioluminescence, viable counting and microscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Establishment of a real-time PCR-based approach for accurate quantification of bacterial RNA targets in water, using Salmonella as a model organism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Advantages and limitations of quantitative PCR (Q-PCR)-based approaches in microbial ecology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

A novel in vitro pharmacokinetic/pharmacodynamic model based on two-compartment open model used to simulate serum drug concentration-time profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Mechanisms of biofilm resistance to antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Antibiotic resistance of Pseudomonas aeruginosa colonizing a urinary catheter in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Method of evaluating effects of antibiotics on bacterial biofilm

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

In vitro models that support adhesion specificity in biofilms of oral bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Animal and cell-culture models for the study of mycobacterial infections and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

An in vitro model of the urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

An in-vitro model simulating the hydrokinetic aspects of the treatment of bacterial cystitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Artificial dental plaque biofilm model systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

A mixed-culture chemostat system to predict the effect of anti-microbial agents on the oral flora: preliminary studies using chlorhexidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Caspofungin in combination with amphotericin B against Candida parapsilosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

A new in-vitro kinetic model to study the pharmacodynamics of antifungal agents: inhibition of the fungicidal activity of amphotericin B against Candida albicans by voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP434

21 January 2018

Identifiers

DOI

10.1093/JAC/DKP434

1 reference

21 August 2017

1 reference